Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies

Tau is a microtubule-associated protein and a key regulator of microtubule stabilization as well as the main component of neurofibrillary tangles—a principle neuropathological hallmark of Alzheimer’s disease (AD)—as well as pleomorphic neuronal and glial inclusions in neurodegenerative tauopathies. Cross-sectional studies of neurofibrillary pathology in AD reveal a stereotypic spatiotemporal pattern of neuronal vulnerability that correlates with disease severity; however, the relationship of this pattern to disease progression is less certain and exceptions to the typical pattern have been described in a subset of AD patients. The basis for the selective vulnerability of specific populations of neurons to tau pathology and cell death is largely unknown, although there have been a number of hypotheses based upon shared properties of vulnerable neurons (e.g., degree of axonal myelination or synaptic plasticity). A recent hypothesis for selective vulnerability takes into account the emerging science of functional connectivity based upon resting state functional magnetic resonance imaging, where subsets of neurons that fire synchronously define patterns of degeneration similar to specific neurodegenerative disorders, including various tauopathies. In the past 6 years, the concept of tau propagation has emerged from numerous studies in cell and animal models suggesting that tau moves from cell-to-cell and that this may trigger aggregation and region-to-region spread of tau pathology within the brain. How the spread of tau pathology relates to functional connectivity is an area of active investigation. Observations of templated folding and propagation of tau have prompted comparisons of tau to prions, the pathogenic proteins in transmissible spongiform encephalopathies. In this review, we discuss the most compelling studies in the field, discuss their shortcomings and consider their implications with respect to human tauopathies as well as the controversy that tauopathies may be prion-like disorders.

[1]  J. Trojanowski,et al.  Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains , 2015, Acta Neuropathologica.

[2]  T. Uchihara,et al.  Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy , 2004, Acta Neuropathologica.

[3]  John Q Trojanowski,et al.  Neurodegenerative Tauopathies Human Disease and Transgenic Mouse Models , 1999, Neuron.

[4]  R. Crowther,et al.  Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. , 1989, The EMBO journal.

[5]  P. Szekeres,et al.  Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates , 2014, The Journal of Biological Chemistry.

[6]  H. Braak,et al.  Vulnerability of Select Neuronal Types to Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[7]  A. Hirano,et al.  Alzheimer's neurofibrillary changes. A topographic study. , 1962, Archives of neurology.

[8]  P. Davies,et al.  Conformational change as one of the earliest alterations of tau in Alzheimer’s disease , 2000, Neurobiology of Aging.

[9]  F. van Leuven,et al.  Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice* , 2005, Journal of Biological Chemistry.

[10]  P. Verstreken,et al.  Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. , 2015, Cell reports.

[11]  L. Chang,et al.  Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease , 1995, Neurology.

[12]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[13]  D. Quartermain,et al.  Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.

[14]  Stella Aronov,et al.  Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules , 2002, Journal of Cell Science.

[15]  T. Arendt Neurodegeneration and plasticity , 2004, International Journal of Developmental Neuroscience.

[16]  S. Prusiner Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[17]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[18]  D. Dickson,et al.  Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. , 2008, Brain : a journal of neurology.

[19]  A. Lees,et al.  Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[20]  M. Diamond,et al.  Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation* , 2015, The Journal of Biological Chemistry.

[21]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[22]  D. Hanger,et al.  Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. , 1991, The Biochemical journal.

[23]  P. Harrison,et al.  Classifying prion and prion-like phenomena , 2014, Prion.

[24]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[25]  M. Margittai,et al.  Amplification of Tau Fibrils from Minute Quantities of Seeds , 2014, Biochemistry.

[26]  J. Trojanowski,et al.  Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice , 2015, Neurobiology of Disease.

[27]  L. Grinberg,et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.

[28]  T. Iwatsubo,et al.  1 SEEDED AGGREGATION AND TOXICITY OF α-SYNUCLEIN AND TAU : CELLULAR MODELS OF NEURODEGENERATIVE DISEASES , 2010 .

[29]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[30]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[31]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[32]  V. Lee,et al.  Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.

[33]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[34]  Zeshan Ahmed,et al.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.

[35]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[36]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[37]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Hyman,et al.  Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease , 2015, Acta neuropathologica communications.

[39]  J. Trojanowski,et al.  Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. , 2013, JAMA neurology.

[40]  William T. Hu,et al.  Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease , 2014, Nature Medicine.

[41]  J. Trojanowski,et al.  Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.

[42]  Julie A. Harris,et al.  Human P301L-Mutant Tau Expression in Mouse Entorhinal-Hippocampal Network Causes Tau Aggregation and Presynaptic Pathology but No Cognitive Deficits , 2012, PloS one.

[43]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[44]  Clemens F. Kaminski,et al.  Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology* , 2013, The Journal of Biological Chemistry.

[45]  T. Uchihara,et al.  Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method , 2001, Acta Neuropathologica.

[46]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.

[47]  David W. Colby,et al.  Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. , 2013, Biochemistry.

[48]  T. Golde,et al.  Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission , 2015, Acta Neuropathologica.

[49]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[50]  E. Mandelkow,et al.  Proteolytic processing of tau. , 2010, Biochemical Society transactions.

[51]  Juan Zhou,et al.  Network Dysfunction in Alzheimer’s Disease and Frontotemporal Dementia: Implications for Psychiatry , 2014, Biological Psychiatry.

[52]  Jun Wang,et al.  Paired Helical Filaments from Alzheimer Disease Brain Induce Intracellular Accumulation of Tau Protein in Aggresomes* , 2012, The Journal of Biological Chemistry.

[53]  Andrew Trujillo,et al.  Intrinsic connectivity network disruption in progressive supranuclear palsy , 2013, Annals of neurology.

[54]  A. Delacourte,et al.  Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease , 1999, Brain pathology.

[55]  K S Kosik,et al.  The Molecular and Cellular Biology of Tau , 1993, Brain pathology.

[56]  H. Braak,et al.  Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? , 2011, Acta Neuropathologica.

[57]  M. Vandermeeren,et al.  Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. , 1993, Journal of neurochemistry.

[58]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[59]  W. Kamphorst,et al.  Selective Deposition of Mutant Tau in the FTDP‐17 Brain Affected by the P301L Mutation , 2001, Journal of neuropathology and experimental neurology.

[60]  D. Řípová,et al.  Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease. , 2013, Journal of neuropathology and experimental neurology.

[61]  K. Bötzel,et al.  Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation , 2012, Experimental Neurology.

[62]  H. Huynh,et al.  Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. , 2011, Biochemistry.

[63]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[64]  R. Neve,et al.  The microtubule binding domain of tau protein , 1989, Neuron.

[65]  Dennis W. Dickson,et al.  Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.

[66]  B. Hyman,et al.  Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease , 2013, The Journal of Neuroscience.

[67]  D. Selkoe,et al.  C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death , 2015, The Journal of Neuroscience.

[68]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[69]  K. Jellinger,et al.  Senile Dementia with Tangles (Tangle Predominant Form of Senile Dementia) , 1998, Brain pathology.

[70]  D. Crapper,et al.  Paired helical filaments of the Alzheimer type in cultured neurones , 1978, Nature.

[71]  M. Palmer,et al.  Unaltered susceptibility to BSE in transgenic mice expressing human prion protein , 1995, Nature.

[72]  S. Hirai,et al.  Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau , 1995, Neuroscience Letters.

[73]  M. Mesulam,et al.  Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease , 2007, Neurobiology of Aging.

[74]  P. Davies,et al.  Alzheimer‐related neuronal protein A68: Specificity and distribution , 1987, Annals of neurology.

[75]  G. Bormans,et al.  Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice , 2015, Acta Neuropathologica.

[76]  D. Gajdusek,et al.  Nucleation of Amyloidogenesis in Infectious and Noninfectious Amyloidoses of Brain , 1994, Annals of the New York Academy of Sciences.

[77]  M. Jeffrey,et al.  PrP in pathology and pathogenesis in scrapie-infected mice , 1994, Molecular Neurobiology.

[78]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[79]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[80]  E. Sigurdsson,et al.  Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.

[81]  D. Holtzman,et al.  Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.

[82]  Michael J. Yetman,et al.  Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex , 2015, Brain Structure and Function.

[83]  S ORAM,et al.  STAPHYLOCOCCI RESISTANT TO NEOMYCIN AND BACITRACIN. , 1965, Lancet.

[84]  Adriana B Ferreira,et al.  The Generation of a 17 kDa Neurotoxic Fragment: An Alternative Mechanism by which Tau Mediates β-Amyloid-Induced Neurodegeneration , 2005, The Journal of Neuroscience.

[85]  J. B. Thomas,et al.  Tau-beta-galactosidase, an axon-targeted fusion protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[86]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[87]  U. Sengupta,et al.  Characterization of tau oligomeric seeds in progressive supranuclear palsy , 2014, Acta neuropathologica communications.

[88]  K. Kosik,et al.  Structure and novel exons of the human tau gene. , 1992, Biochemistry.

[89]  J. Holton,et al.  Cytoskeletal pathology in familial cerebral amyloid angiopathy (British type) with non-neuritic amyloid plaque formation , 1999, Acta Neuropathologica.

[90]  Markus Tolnay,et al.  “Prion‐Like” Templated Misfolding in Tauopathies , 2013, Brain pathology.

[91]  A. Ittner,et al.  Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice , 2011, PloS one.

[92]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[93]  Ayodeji A. Asuni,et al.  Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.

[94]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[95]  D. Holtzman,et al.  In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice , 2011, The Journal of Neuroscience.

[96]  Bernardino Ghetti,et al.  Familial Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles , 1994, Molecular Neurobiology.

[97]  Bengt Winblad,et al.  Defective brain microtubule assembly in Alzheimer??s disease , 1987 .

[98]  C. Cotman,et al.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. , 2004, The Journal of clinical investigation.

[99]  H. Vinters,et al.  Pre‐synaptic C‐terminal truncated tau is released from cortical synapses in Alzheimer's disease , 2015, Journal of neurochemistry.

[100]  M. Mesulam,et al.  Cholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum , 2004, Annals of neurology.

[101]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[102]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[103]  J. Growdon,et al.  Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype , 1995, Annals of neurology.

[104]  D. Dickson,et al.  An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies , 2006, Acta Neuropathologica.

[105]  Nigel J. Cairns,et al.  Proteopathic tau seeding predicts tauopathy in vivo , 2014, Proceedings of the National Academy of Sciences.

[106]  Wen-Lang Lin,et al.  Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration , 2006, Journal of neuropathology and experimental neurology.